Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD-mediated pyroptosis in colorectal cancer

Xin Guan , Ruiqi Liu , Bojun Wang , Ruxin Xiong , Luying Cui , Yuanyu Liao , Yuli Ruan , Lin Fang , Xiaolin Lu , Xuefan Yu , Dan Su , Yue Ma , Tianjiao Dang , Zhuo Chen , Yuanfei Yao , Chao Liu , Yanqiao Zhang

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (6) : e1692

PDF
Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (6) : e1692 DOI: 10.1002/ctm2.1692
RESEARCH ARTICLE

Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD-mediated pyroptosis in colorectal cancer

Author information +
History +
PDF

Abstract

• Silencing of NLRP3 limits the GSDMD-dependent pyroptosis in colorectal cancer.

• HDAC2-mediated histone deacetylation leads to epigenetic silencing of NLRP3.

• HDAC2 suppresses the NLRP3 transcription by inhibiting the formation of H3K27ac/BRD4/p-P65 complex.

• Targeting HDAC2 activates pyroptosis and enhances therapeutic effect.

Keywords

colorectal cancer / H3K27ac / HDAC2 / NLRP3 / pyroptosis

Cite this article

Download citation ▾
Xin Guan, Ruiqi Liu, Bojun Wang, Ruxin Xiong, Luying Cui, Yuanyu Liao, Yuli Ruan, Lin Fang, Xiaolin Lu, Xuefan Yu, Dan Su, Yue Ma, Tianjiao Dang, Zhuo Chen, Yuanfei Yao, Chao Liu, Yanqiao Zhang. Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD-mediated pyroptosis in colorectal cancer. Clinical and Translational Medicine, 2024, 14(6): e1692 DOI:10.1002/ctm2.1692

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

MorganE, ArnoldM, GiniA, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72:338-344.

[2]

CiardielloF, Ciardiello D, MartiniG, NapolitanoS, Tabernero J, CervantesA. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022;72:372-401.

[3]

CervantesA, AdamR, RosellóS, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10-32.

[4]

GrotheyA, BlayJY, PavlakisN, Yoshino T, BruixJ. Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treat Rev. 2020;86:101993.

[5]

AzwarS, SeowHF, AbdullahM, Faisal Jabar M, MohtarrudinN. Recent updates on mechanisms of resistance to 5-fluorouracil and reversal strategies in colon cancer treatment. Biology (Basel). 2021;10:854.

[6]

HeinemannV, von Weikersthal LF, DeckerT, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065-1075.

[7]

LoteH, Starling N, PihlakR, GerlingerM. Advances in immunotherapy for MMR proficient colorectal cancer. Cancer Treat Rev. 2022;111:102480.

[8]

TanY, ChenQ, LiX, et al. Pyroptosis: a new paradigm of cell death for fighting against cancer. J Exp Clin Cancer Res. 2021;40:153.

[9]

ZhangZ, ZhouY, ZhaoS, Ding L, ChenB, ChenY. Nanomedicine-enabled/augmented cell pyroptosis for efficient tumor nanotherapy. Adv Sci (Weinh). 2022;9:e2203583.

[10]

WeiX, XieF, ZhouX, et al. Role of pyroptosis in inflammation and cancer. Cell Mol Immunol. 2022;19:971-992.

[11]

LiYT, TanXY, MaLX, et al. Targeting LGSN restores sensitivity to chemotherapy in gastric cancer stem cells by triggering pyroptosis. Cell Death Dis. 2023;14:545.

[12]

WangY, GaoW, ShiX, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547:99-103.

[13]

ShiJ, ZhaoY, WangK, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526:660-665.

[14]

YangJ, LiuZ, WangC, et al. Mechanism of gasdermin D recognition by inflammatory caspases and their inhibition by a gasdermin D-derived peptide inhibitor. Proc Natl Acad Sci U S A. 2018;115:6792-6797.

[15]

LuF, LanZ, XinZ, et al. Emerging insights into molecular mechanisms underlying pyroptosis and functions of inflammasomes in diseases. J Cell Physiol. 2020;235:3207-3221.

[16]

FangY, TangY, HuangB. Pyroptosis: a road to next-generation cancer immunotherapy. Semin Immunol. 2023;68:101782.

[17]

ShadabA, Mahjoor M, Abbasi-KolliM, AfkhamiH, Moeinian P, SafdarianAR. Divergent functions of NLRP3 inflammasomes in cancer: a review. Cell Commun Signal. 2023;21:232.

[18]

TarteyS, Kanneganti TD. Differential role of the NLRP3 inflammasome in infection and tumorigenesis. Immunology. 2019;156:329-338.

[19]

JungG, Hernández-Illán E, MoreiraL, BalaguerF, GoelA. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020;17:111-130.

[20]

ShettyMG, PaiP, DeaverRE, Satyamoorthy K, BabithaKS. Histone deacetylase 2 selective inhibitors: a versatile therapeutic strategy as next generation drug target in cancer therapy. Pharmacol Res. 2021;170:105695.

[21]

HaringM, Offermann S, DankerT, HorstI, Peterhansel C, StamM. Chromatin immunoprecipitation: optimization, quantitative analysis and data normalization. Plant Methods. 2007;3:11.

[22]

YaoY, LiuC, WangB, et al. HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1/RBL2/c-Myc axis. Cancer Lett. 2022;533:215595.

[23]

BuenrostroJD, GiresiPG, ZabaLC, Chang HY, GreenleafWJ. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods. 2013;10:1213-1218.

[24]

YangC, MaL, XiaoD, Ying Z, JiangX, LinY. Integration of ATAC-Seq and RNA-Seq identifies key genes in light-induced primordia formation of Sparassis latifolia. Int J Mol Sci. 2019;21:185.

[25]

QiZP, Yalikong A, ZhangJW, et al. HDAC2 promotes the EMT of colorectal cancer cells and via the modular scaffold function of ENSG00000274093.1. J Cell Mol Med. 2021;25:1190-1197.

[26]

JeongJB, LeeSH. Protocatechualdehyde possesses anti-cancer activity through downregulating cyclin D1 and HDAC2 in human colorectal cancer cells. Biochem Biophys Res Commun. 2013;430:381-386.

[27]

XiY, XuP. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14:101174.

[28]

YanH, LuoB, WuX, et al. Cisplatin induces pyroptosis via activation of MEG3/NLRP3/caspase-1/GSDMD pathway in triple-negative breast cancer. Int J Biol Sci. 2021;17:2606-2621.

[29]

WestbomC, Thompson JK, LeggettA, et al. Inflammasome modulation by chemotherapeutics in malignant mesothelioma. PLoS One. 2015;10:e0145404.

[30]

JohnsonDC, Taabazuing CY, OkondoMC, et al. DPP8/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia. Nat Med. 2018;24:1151-1156.

[31]

ZhangY, LiF, WangL, Lou Y. A438079 affects colorectal cancer cell proliferation, migration, apoptosis, and pyroptosis by inhibiting the P2×7 receptor. Biochem Biophys Res Commun. 2021;558:147-153.

[32]

FengWQ, ZhangYC, XuZQ, et al. IL-17A-mediated mitochondrial dysfunction induces pyroptosis in colorectal cancer cells and promotes CD8 + T-cell tumour infiltration. J Transl Med. 2023;21:335.

[33]

JuM, BiJ, WeiQ, et al. Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer. Brief Bioinform. 2021;22:bbaa345.

[34]

SharmaBR, Kanneganti TD. NLRP3 inflammasome in cancer and metabolic diseases. Nat Immunol. 2021;22:550-559.

[35]

XuJ, Núñez G. The NLRP3 inflammasome: activation and regulation. Trends Biochem Sci. 2023;48:331-344.

[36]

ZhuP, MartinE, MengwasserJ, Schlag P, JanssenKP, GöttlicherM. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004;5:455-463.

[37]

BacklundMG, MannJR, HollaVR, et al. Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res. 2008;68:9331-9337.

[38]

MariadasonJM. HDACs and HDAC inhibitors in colon cancer. Epigenetics. 2008;3:28-37.

[39]

BartosovicM, KabbeM, Castelo-BrancoG. Single-cell CUT&Tag profiles histone modifications and transcription factors in complex tissues. Nat Biotechnol. 2021;39:825-835.

[40]

ZhengX, Diktonaite K, QiuH. Epigenetic reader bromodomain-containing protein 4 in aging-related vascular pathologies and diseases: molecular basis, functional relevance, and clinical potential. Biomolecules. 2023;13:1135.

[41]

DongJ, LiJ, LiY, MaZ, YuY, WangCY. Transcriptional super-enhancers control cancer stemness and metastasis genes in squamous cell carcinoma. Nat Commun. 2021;12:3974.

[42]

NordJA, Wynia-Smith SL, GehantAL, et al. N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells. Front Endocrinol (Lausanne). 2022;13:923925.

[43]

TangW, ZhouW, XiangL, et al. The p300/YY1/miR-500a-5p/HDAC2 signalling axis regulates cell proliferation in human colorectal cancer. Nat Commun. 2019;10:663.

[44]

ConteM, Di Mauro A, CapassoL, et al. Targeting HDAC2-mediated immune regulation to overcome therapeutic resistance in mutant colorectal cancer. Cancers (Basel). 2023;15:1960.

[45]

SinghM, KumarV, SehrawatN, et al. Current paradigms in epigenetic anticancer therapeutics and future challenges. Semin Cancer Biol. 2022;83:422-440.

[46]

BiersackB, PolatS, HöpfnerM. Anticancer properties of chimeric HDAC and kinase inhibitors. Semin Cancer Biol. 2022;83:472-486.

[47]

RaiS, KimWS, AndoK, et al. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica. 2023;108:811-821.

[48]

GromekSM, de Mayo JA, MaxwellAT, et al. Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity. Bioorg Med Chem. 2016;24:5183-5196.

[49]

ZhangT, WeiD, LuT, et al. CAY10683 and imatinib have synergistic effects in overcoming imatinib resistance via HDAC2 inhibition in chronic myeloid leukemia. RSC Adv. 2020;10:828-844.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

AI Summary AI Mindmap
PDF

154

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/